Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
MWN-AI** Summary
Monopar Therapeutics Inc. recently announced that the Journal of Hepatology has published a notable peer-reviewed Letter to the Editor from a group of prominent physicians specializing in Wilson disease. This letter, titled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease,” discusses significant findings regarding the drug ALXN1840, which is under development for this rare genetic condition characterized by dangerous copper accumulation in the body.
The physicians highlighted that previous conclusions from the Phase 2 ALXN1840-WD-204 study indicated the drug did not enhance copper excretion due to a methodological error in the copper balance assessment. By refining their analysis to account for additional loss routes of copper, it was revealed that ALXN1840 indeed significantly improved copper balance in treated patients. The findings indicated substantial improvements with statistical significance—during the 15 mg/day treatment period, the mean daily difference in copper excretion was -0.367 mg (p=0.005), and overall treatment periods showed a mean daily difference of -0.289 mg (p=0.023). Cumulatively, a significant change of -6.08 mg from baseline was noted.
Monopar Therapeutics, which specializes in innovative treatments for unmet medical needs, continues to focus on developing ALXN1840 alongside other programs aimed at advanced cancers. As the company advances through regulatory processes and commercialization, uncertainties remain regarding market acceptance and financial stability, with significant risks associated with drug development.
Investors and stakeholders in biopharmaceuticals should monitor Monopar's progress, given the potential advancements in the treatment landscape for Wilson disease through ALXN1840.
MWN-AI** Analysis
Monopar Therapeutics Inc.'s recent announcement regarding the publication of a peer-reviewed letter in the Journal of Hepatology, detailing the efficacy of ALXN1840 in improving copper balance in Wilson disease patients, positions the company favorably in a niche but critical market. The analysis presented refutes the prior clinical conclusions, demonstrating improvements in copper excretion, thereby enhancing the credibility and potential market value of ALXN1840.
Investors should note that Wilson disease is a rare but debilitating condition, creating a targeted market opportunity. Given the confirmed improvement in copper balance, Monopar is now better positioned to pave the way for regulatory discussions and potentially expedited approval processes. The statistical significance (p=0.005 for the 15 mg/day treatment and p=0.023 overall) underscores the potential therapeutic benefit and could attract attention from larger pharmaceutical companies for partnerships or acquisitions.
However, investors should remain cognizant of the risks involved, notably the uncertainties surrounding regulatory pathways and the competitive landscape post-approval. The biopharmaceutical market is notoriously volatile, and Monopar's success heavily depends on clinical trial outcomes and subsequent market reception. The company’s financial health is another critical aspect; its ability to fund ongoing clinical trials and development efforts will influence its long-term viability.
Therefore, while the recent development is a positive indicator for Monopar’s prospects, investors are advised to approach with caution. It may be wise to monitor ongoing clinical results closely, as well as press releases regarding funding and partnerships, which can significantly affect stock performance. Potential investors may consider entering gradually, taking advantage of market fluctuations, while keeping an eye on broader market trends in biotech and health care.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor ( link ), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain.
In the Letter to the Editor, the authors explain that the earlier conclusion from the Phase 2 ALXN1840-WD-204 study (NCT04573309) – that ALXN1840 did not promote copper excretion – was based on a methodological limitation in the copper balance equation, which only accounted for certain routes of copper loss. By controlling for the other routes of copper loss by comparing pre- and post-ALXN1840 treatment, the analysis demonstrates that ALXN1840 statistically significantly improved copper balance (increases copper excretion) over the duration of the study. Supplementary materials published alongside the Letter illustrate how the same primary copper balance data produced both the prior sponsor’s analysis as well as the results presented in the Letter.
Key findings on the effect of ALXN1840 on copper balance reported in the Letter:
- 15 mg/day treatment period: mean daily difference -0.367 mg (p=0.005)
- Overall treatment period (includes patients with dose changes to 15 mg every other day and to 30 mg/day): mean daily difference -0.289 mg (p=0.023)
- Cumulative mean change from baseline: -6.08 mg (95% CI: -10.18 mg to -1.98 mg), see graphs below
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Contact:
Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/9b7c7917-6cae-4321-bd40-82479a25b590
https://www.globenewswire.com/NewsRoom/AttachmentNg/38d44bf0-8b61-4cb7-b5a6-99b64ede71cb
FAQ**
How does Monopar Therapeutics Inc. MNPR plan to address potential regulatory challenges for ALXN1840 following the recent findings published in the Journal of Hepatology?
What strategies is Monopar Therapeutics Inc. MNPR considering to enhance market acceptance and competitiveness for ALXN1840 once it receives marketing approval?
Given the positive results from the ALXN1840 study, how will Monopar Therapeutics Inc. MNPR secure funding to support further clinical trials and commercialization?
How does Monopar Therapeutics Inc. MNPR intend to communicate the significance of the copper balance improvements to healthcare providers and patients in the Wilson disease community?
**MWN-AI FAQ is based on asking OpenAI questions about Monopar Therapeutics Inc. (NASDAQ: MNPR).
NASDAQ: MNPR
MNPR Trading
3.73% G/L:
$58.625 Last:
74,240 Volume:
$57.82 Open:
